IOWA CITY — News this week that Americans now have a fourth COVID-19 vaccine option — one closer to more traditional vaccines used to combat flu, for example — came about thanks, in part, to ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circulating nationwide as ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...

Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.

Dr Sara Brenner, the FDA's principal deputy commissioner, has paused the approval process for Novavax's Covid-19 vaccine by requesting additional data.Source: Novavax.This intervention coincides with ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Novavax reported fourth-quarter earnings of 11 cents, a ...